| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
|
Sakai, Daisuke
|
|
2017
|
80 |
6 |
p. 1197-1207
|
article
|
| 2 |
A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin
|
Di Cesare Mannelli, Lorenzo
|
|
2017
|
80 |
6 |
p. 1091-1103
|
article
|
| 3 |
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
|
Sato, Yasushi
|
|
2017
|
80 |
6 |
p. 1133-1139
|
article
|
| 4 |
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
|
Takahara, Naminatsu
|
|
2017
|
80 |
6 |
p. 1105-1112
|
article
|
| 5 |
Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)
|
Yoshino, Kiyoshi
|
|
2017
|
80 |
6 |
p. 1239-1247
|
article
|
| 6 |
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
|
Bent, Martin van den
|
|
2017
|
80 |
6 |
p. 1209-1217
|
article
|
| 7 |
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
|
Matsubara, Nobuaki
|
|
2017
|
80 |
6 |
p. 1073-1077
|
article
|
| 8 |
Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
|
Giri, Nagdeep
|
|
2017
|
80 |
6 |
p. 1249-1260
|
article
|
| 9 |
Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
|
Li, Chunze
|
|
2017
|
80 |
6 |
p. 1079-1090
|
article
|
| 10 |
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
|
Verheijen, R. B.
|
|
2017
|
80 |
6 |
p. 1171-1178
|
article
|
| 11 |
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
|
Verheijen, R. B.
|
|
|
80 |
6 |
p. 1171-1178
|
article
|
| 12 |
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
|
de Jong, Jan
|
|
2017
|
80 |
6 |
p. 1227-1237
|
article
|
| 13 |
Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
|
Redondo, Andrés
|
|
2017
|
80 |
6 |
p. 1113-1131
|
article
|
| 14 |
Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer
|
Kobayashi, Satoshi
|
|
2017
|
80 |
6 |
p. 1189-1196
|
article
|
| 15 |
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
|
Matsubara, Nobuaki
|
|
2017
|
80 |
6 |
p. 1063-1072
|
article
|
| 16 |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
|
Chen, Shang-Chiung
|
|
2017
|
80 |
6 |
p. 1147-1159
|
article
|
| 17 |
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine
|
Ciccolini, Joseph
|
|
2017
|
80 |
6 |
p. 1265-1266
|
article
|
| 18 |
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer
|
Lenz, Heinz-Josef
|
|
2017
|
80 |
6 |
p. 1161-1169
|
article
|
| 19 |
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea
|
Masab, Muhammad
|
|
2017
|
80 |
6 |
p. 1055-1062
|
article
|
| 20 |
The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies
|
Lucchesi, Maurizio
|
|
|
80 |
6 |
p. 1047-1053
|
article
|
| 21 |
The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies
|
Lucchesi, Maurizio
|
|
2017
|
80 |
6 |
p. 1047-1053
|
article
|
| 22 |
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer
|
Koch, Kevin M.
|
|
2017
|
80 |
6 |
p. 1141-1146
|
article
|
| 23 |
The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer
|
Nomura, Masatoshi
|
|
2017
|
80 |
6 |
p. 1219-1226
|
article
|
| 24 |
Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification
|
McAtee, Casey L.
|
|
2017
|
80 |
6 |
p. 1261-1264
|
article
|
| 25 |
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
|
Chen, Kaiyan
|
|
2017
|
80 |
6 |
p. 1179-1187
|
article
|
Journal description